Abstract:Abstract Background: For patients with HR+/HER2− advanced breast cancer who experience disease progression on endocrine therapy, cytotoxic chemotherapy (chemo) regimens are standard of care. Adding immunotherapy to chemo may improve patient outcomes. The anti-PD-1 antibody pembrolizumab (pembro) has demonstrated efficacy in patients with triple-negative breast cancer, including those with metastatic disease (KEYNOTE-355) and with early-stage disease (KEYNOTE-522). The phase 1b KEYNOTE-028 trial showed durable activity with pembro monotherapy among patients with previously treated HR+/HER2−, PD-L1-positive (ie, combined positive score [CPS] ≥1) advanced breast cancer. KEYNOTE-B49 (NCT04895358) is a phase 3, randomized, double-blind study comparing pembro plus chemo vs placebo plus chemo in patients with PD-L1-positive, HR+/HER2− locally recurrent inoperable or metastatic breast cancer who progressed on prior endocrine therapy. Methods: Approximately 800 patients with HR+/HER2− locally recurrent inoperable or metastatic breast cancer who are candidates for chemo (no prior chemo for metastatic disease) and who have a PD-L1 CPS ≥1 and documented progression on prior endocrine therapy will be enrolled. Prior endocrine therapy comprises ≥2 lines (≥1 in combination with a CDK4/6 inhibitor) in the metastatic setting or 1 line plus CDK4/6 inhibitor treatment with relapse within 24 months of surgery in the adjuvant setting. Patients without CDK4/6 inhibitor treatment may enroll if they have progression within 6 months of starting endocrine therapy for metastatic disease and within 24 months of surgery while on adjuvant endocrine therapy. Patients are randomized 1:1 to receive pembro 200 mg IV or placebo Q3W, each in combination with investigator’s choice of 1 of 4 chemo regimens: paclitaxel 90 mg/m2 IV on days 1, 8, and 15 Q4W; nab-paclitaxel 100 mg/m2 IV on days 1, 8, and 15 Q4W; liposomal doxorubicin 50 mg/m2 IV on day 1 Q4W; or capecitabine 1000 mg/m2 PO BID on days 1-14 Q3W. Randomization is stratified by tumor PD-L1 expression (CPS 1-9 vs ≥10), visceral metastases (yes vs no), and chemo (taxanes vs liposomal doxorubicin vs capecitabine). Participants, investigators, and study personnel are blinded to treatment assignment and tumor PD-L1 status. Treatment is continued until radiographic disease progression, unacceptable toxicity, withdrawal, or, for pembro/placebo, completion of 35 administrations (~2 years); chemo can be continued per investigator discretion. Tumor PD-L1 status is determined centrally using the PD-L1 IHC 22C3 pharmDx assay (Agilent Technologies; Carpinteria, CA, USA). Radiologic assessments are performed every 9 weeks through the first 54 weeks and then every 12 weeks thereafter to detect evidence of progression. AEs occurring from randomization until 30 days after treatment discontinuation (90 days for serious AEs) are graded per NCI-CTCAE v 5.0. Primary endpoints are PFS per RECIST v1.1 by blinded independent central review in patients with PD-L1 CPS ≥10 and ≥1 tumors, separately. A key secondary endpoint is OS; additional secondary endpoints are investigator-assessed PFS, ORR, disease control rate, duration of response, and health-related quality of life using EORTC QLQ-C30 (each assessed in patients with PD-L1 CPS ≥10 and ≥1 tumors), as well as safety in the overall population. The family-wise type-I error rate is controlled at 0.025 (one-sided) across the PFS and OS endpoints. PFS and OS will be estimated using the Kaplan-Meier method. Treatment differences will be assessed using a stratified log-rank test, and HRs and 95% CIs will be determined using a stratified Cox proportional hazards model. Enrollment is ongoing. Citation Format: Peter Schmid, Carlos Baccan, Zifang Guo, Kostas Tryfonidis, Hope S. Rugo. KEYNOTE-B49: A phase 3, randomized, double-blind, placebo-controlled study of pembrolizumab plus chemotherapy in patients with HR+/HER2− locally recurrent inoperable or metastatic breast cancer [abstract]. In: Proceedings of the 2021 San Antonio Breast Cancer Symposium; 2021 Dec 7-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2022;82(4 Suppl):Abstract nr OT1-18-06.

Phase 1b/2 study of pembrolizumab plus belzutifan and belzutifan alone in patients with docetaxel-treated metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 cohort J.

Pembrolizumab (pembro) plus lenvatinib (lenva) in patients (pts) with docetaxel-pretreated, metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 cohort E.

Phase 1b/2 study of pembrolizumab (pembro) plus platinum/etoposide and platinum/etoposide for neuroendocrine metastatic prostate cancer (NEPC): KEYNOTE-365 cohort I.

Coformulation of pembrolizumab and vibostolimab in patients (pts) with docetaxel-pretreated metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 cohort G.

Peapod FOS trial: A phase 2 clinical trial of pembrolizumab in combination with carboplatin and cabazitaxel in aggressive variant metastatic castration-resistant prostate cancer.

Pembrolizumab plus enzalutamide for metastatic castration-resistant prostate cancer progressing on enzalutamide: cohorts 4 and 5 of the phase 2 KEYNOTE-199 study

Phase II trial of Pembrolizumab and Anti-CD3 x Anti-HER2 Bispecific Antibody Armed Activated T Cells in Metastatic Castrate Resistant Prostate Cancer

Phase II study of pembrolizumab in combination with radiation with or without olaparib in localized high-risk prostate cancer.

ENGOT-en11/GOG-3053/KEYNOTE-B21: Phase 3 Study of Pembrolizumab or Placebo in Combination with Adjuvant Chemotherapy With/without Radiotherapy in Patients with Newly Diagnosed High-Risk Endometrial Cancer.

Phase II trial of pembrolizumab for patients suffering from metastatic castration resistant prostate cancer (mCRPC) with DNA repair defects, high tumour mutation burden, and/or high CD3 counts (PERSEUS1).

A phase Ib/II study (IMMCO-1) of atezolizumab plus tivozanib in castrate-resistant prostate cancer and certain other immunologically cold tumors.

Randomized Phase II Study of Durvalumab with or without Tremelimumab in Patients with Metastatic Castration Resistant Prostate Cancer.

Abstract OT1-18-06: KEYNOTE-B49: A phase 3, randomized, double-blind, placebo-controlled study of pembrolizumab plus chemotherapy in patients with HR+/HER2− locally recurrent inoperable or metastatic breast cancer

Phase I/II trial of LAVA-1207, a novel bispecific gamma-delta T-cell engager alone, or with low dose IL-2 or pembrolizumab, in metastatic castration resistant prostate cancer (mCRPC).

A phase 2 study of cabozantinib and nivolumab in metastatic castration-resistant prostate cancer (CANOPY).

A randomized phase II study of apalutamide with or without carotuximab (ant-CD105) in metastatic, castration-resistant prostate cancer.

Randomized Phase II Study Evaluating the Addition of Pembrolizumab to Radium-223 in Metastatic Castration-resistant Prostate Cancer

Phase 2 trial of T-cell activation using MVI-816 and pembrolizumab in patients with metastatic, castration-resistant prostate cancer (mCRPC)

DynAMo: A dynamic allocation modular sequential trial of approved and promising therapies in men with metastatic CRPC.

A single arm, phase I/II trial of neoadjuvant androgen deprivation, darolutamide, and ipatasertib in men with localized, high-risk prostate cancer.

45 INTerpath-004: A phase 2, randomized, double-blind study of pembrolizumab with V940 (mRNA-4157) or placebo in the adjuvant treatment of renal cell carcinoma